Jeil Pharmaceutical Co.,Ltd (271980.KS)
KRW 11640.0
(-5.6%)
KRW 11640.0
(-5.6%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 18.65 Billion KRW | 495.8% |
| 2022 | -1.2 Billion KRW | -234.78% |
| 2021 | -2.01 Billion KRW | -84.87% |
| 2020 | 22.59 Billion KRW | 166.72% |
| 2019 | 8.5 Billion KRW | -33.45% |
| 2018 | 13.11 Billion KRW | 58.31% |
| 2017 | 8.22 Billion KRW | -51.72% |
| 2016 | 22.25 Billion KRW | -21.19% |
| 2015 | 25.08 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -12.24 Billion KRW | -1489.87% |
| 2024 Q1 | 398.84 Million KRW | 146.61% |
| 2023 FY | - KRW | 495.8% |
| 2023 Q3 | -490.15 Million KRW | -186.25% |
| 2023 Q2 | 568.31 Million KRW | -96.95% |
| 2023 Q1 | 18.64 Billion KRW | 808.23% |
| 2023 Q4 | 1.11 Billion KRW | 328.1% |
| 2022 Q4 | -2.63 Billion KRW | -237.48% |
| 2022 Q1 | -1.3 Billion KRW | 62.09% |
| 2022 Q2 | 8.8 Million KRW | 100.67% |
| 2022 FY | - KRW | -234.78% |
| 2022 Q3 | -780.08 Million KRW | -8958.74% |
| 2021 Q4 | -3.45 Billion KRW | -248.31% |
| 2021 Q2 | 3.5 Billion KRW | 215.03% |
| 2021 Q1 | 1.11 Billion KRW | -74.95% |
| 2021 FY | - KRW | -84.87% |
| 2021 Q3 | 2.32 Billion KRW | -33.62% |
| 2020 Q3 | 3.6 Billion KRW | -21.55% |
| 2020 Q1 | 8.18 Billion KRW | 217.96% |
| 2020 FY | - KRW | 166.72% |
| 2020 Q4 | 4.44 Billion KRW | 23.41% |
| 2020 Q2 | 4.59 Billion KRW | -43.87% |
| 2019 FY | - KRW | -33.45% |
| 2019 Q3 | 5 Billion KRW | -24.52% |
| 2019 Q2 | 6.63 Billion KRW | 64.74% |
| 2019 Q1 | 4.02 Billion KRW | 0.98% |
| 2019 Q4 | -6.93 Billion KRW | -238.47% |
| 2018 Q1 | 3.08 Billion KRW | 96.08% |
| 2018 FY | - KRW | 58.31% |
| 2018 Q4 | 3.98 Billion KRW | 20.4% |
| 2018 Q3 | 3.31 Billion KRW | 25.94% |
| 2018 Q2 | 2.63 Billion KRW | -14.75% |
| 2017 Q2 | 677.17 Million KRW | 0.0% |
| 2017 Q4 | 1.57 Billion KRW | -23.64% |
| 2017 FY | - KRW | -51.72% |
| 2017 Q3 | 2.06 Billion KRW | 204.37% |
| 2016 FY | - KRW | -21.19% |
| 2015 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -283.976% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 86.804% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 129.132% |
| HANDOK Inc. | 35.06 Billion KRW | 46.802% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 1899.661% |
| Yuhan Corporation | 127.43 Billion KRW | 85.361% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 50.282% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 186.016% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 94.23% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -273.82% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -23.393% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -445.308% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -312.134% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 47.431% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -283.976% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 200.991% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -184.591% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 137.846% |
| JW Holdings Corporation | 187.88 Billion KRW | 90.071% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 136.415% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 93.423% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 79.091% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 150.328% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -41.222% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -57.719% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -283.976% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 66.065% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 88.688% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 79.091% |
| Yuhan Corporation | 127.43 Billion KRW | 85.361% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 44.274% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -143.859% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 75.782% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 79.091% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 49.078% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 73.644% |
| CKD Bio Corp. | -1.63 Billion KRW | 1244.157% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 62.535% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 42.709% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 49.322% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 150.328% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 70.049% |
| Boryung Corporation | 114.28 Billion KRW | 83.677% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 161.027% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -23.393% |
| JW Lifescience Corporation | 50.82 Billion KRW | 63.299% |